Entry Type
Name
Value
Parent Entry
Pharmacology Data Field
- PubChem: 13-27 h (35 μg ethinyl estradiol with 1 mg norethindrone)
- 7.7 h (single oral dose)
- PubChem: 36 +/-
13 h
Ethinyl Estradiol (API)
Pharmacology Data Field
97% bound. Mainly to serum albumin. No binding to SHBG, but induces SHBG synthesis.
Ethinyl Estradiol (API)
Physical & Chemical Properties Data Field
180-186 °C
(if polymorphic modification: 142-146 °C)
Ethinyl Estradiol (API)
Physical & Chemical Properties Data Field
BP: practically insoluble in water.
PubChem: 11.3 mg/L water at 27 °C.
PubChem, BP:
1 part in 6 of ethanol, 1 in 4 of ether, 1 in 5 of acetone, 1 in 4 of dioxane, and 1 in 20 of chloroform. Soluble in vegetable oils, and in solutions of fixed alkali hydroxides (e.g. NaOH, KOH)
Ethinyl Estradiol (API)
Physical & Chemical Properties Data Field
Pubchem/Toxnet:
[3.5°] at 24° C/D (c = 2 in dioxane); [-29.5°] at 24° C/D (c = 2 in pyridine)
USP: -28° to -29.5°, 50 mg/mL in colorless pyridine from a freshly opened container
Ethinyl Estradiol (API)
Physical & Chemical Properties Data Field
7.94x10-12 atm-cu m/mol at 25° C (est.)
Ethinyl Estradiol (API)
Pharmacology Data Field
Primarily in urine with sulfate and glucuronide conjugates. Some fecal excretion. Very small amounts excreted in milk.
Ethinyl Estradiol (API)
Pharmacology Data Field
2-3 h
Ethinyl Estradiol (API)
Toxicology Data Field
Adverse effects attributed to estrogenic and metabolic effects. Water and sodium retention, which may lead to weight gain, edema, and tender breast enlargement. Changes in libido and withdrawal vaginal bleeding. Liver function impairment, jaundice, and gallstones may occur. Headache, depression, dizziness, glucose intolerance, and a sensitivity to contact lenses have been reported. Nausea, vomiting and break through vaginal bleeding are not uncommon. Dermatological effects include chloasma, melasma, rashes, and urticaria. Erytheme multiforme and erytheme nodosum occur. Hypertension and thromoboembolic disease are reported.
Ortho Evra adverse effects: breast symptoms, headache, application site reaction, nausea, upper respiratory infection, menstrual cramps, abdominal pain.
Ethinyl Estradiol (API)
Toxicology Data Field
There is sufficient evidence in humans for the carcinogenicity of post-menopausal estrogen therapy.
Ethinyl Estradiol (API)